Laigo Bio BV has raised €11.5 million (US$13.7 million) in a seed round for the further development of a new approach to ...

Biopharma financing activity from January through November reveals an environment that has cycled through dramatic peaks and ...

Positive efficacy results led to Praxis Precision Medicines Inc.’s phase II Embold study in developmental and epileptic ...

The ALS Association has announced the recipients of its 2025 Hoffman ALS Clinical Trial Awards. These research grants, worth ...

Receptor-interacting protein kinase 1 (RIPK1) helps promote the survival of cancer cells, and degrading it can sensitize ...

The overexpression of ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1) is tied to poor prognosis in several cancer ...

Crescent Biopharma Inc. has announced a new partnership with Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd. and reported ...

After a more than 13-year period of stability with Janet Woodcock as the head of CDER, with Patrizia Cavazzoni taking charge ...

The U.S. FDA’s recent switch toward more routine use of generalist field investigators might be seen in some quarters as an attempt to do more with less, but a session on the topic at the Food and ...

Freenome Holdings Inc. reported it is going public via a special purpose acquisition company. The company said it expects to raise $330 million, which it plans to use for the 2026 launch of its ...

The first phase of the U.K. synthetic human genome project has successfully completed, realizing key steps in chromosome ...

The first procedure to treat benign prostatic hyperplasia with Boston Scientific Corp.’s next-generation Rezūm EVO Console was successfully completed in the U.K. The device, which recently received CE ...